Trial reportJournal of Crohn's & colitis2017
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Trial report in Journal of Crohn's & colitis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adalimumab for maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2020Pooled it
- Review
- A comparative analysis of corticosteroids and exclusive enteral nutrition induction therapy in children with small bowel Crohn's disease: results of two prospective cohorts.European journal of pediatrics · 2026Observational
- Comparative Predictive Utility of MM-SES-CD and SES-CD for Week 52 Endoscopic Remission in the Ileum and Colon in Crohn's Disease.Inflammatory bowel diseases · 2025Article
- Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study.Journal of Crohn's & colitis · 2025Article
- Novel outcomes in inflammatory bowel disease.Journal of Crohn's & colitis · 2025Review
- Machine learning and metabolomics identify biomarkers associated with the disease extent of ulcerative colitis.Journal of Crohn's & colitis · 2025Article
- Real-World Ustekinumab Experience in Ileum-Dominant Versus Colonic Crohn's Disease.Crohn's & colitis 360 · 2024Article
- Propensity score analysis the clinical characteristics of active distal and extensive ulcerative colitis: a retrospective study.Frontiers in physiology · 2023Article
- Article
- Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?Current research in pharmacology and drug discovery · 2022Review
- Location is important: differentiation between ileal and colonic Crohn's disease.Nature reviews. Gastroenterology & hepatology · 2021Review
- Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine.Expert review of clinical immunology · 2021Review
- Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease.Therapeutic advances in gastroenterology · 2020Article
- Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?Frontiers in medicine · 2020Review
- Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Article
- Targeting mucosal healing in Crohn's disease: what the clinician needs to know.Therapeutic advances in gastroenterology · 2019Review
- Article
- Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?Virchows Archiv : an international journal of pathology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMucosal healing [MH] is an important goal for patients with Crohn's disease [CD], yet is incompletely characterised. We investigated whether MH differed by segments across the colon and ileum in patients who received adalimumab maintenance treatment in the EXTEND study.
methodsIn this double-blind study in adults with moderate to severe ileocolonic CD and mucosal ulceration, all patients received adalimumab induction [Week 0, 160 mg; Week 2, 80 mg]. At Week 4, patients were randomised to 40 mg adalimumab or placebo every other week until Week 52. In this post-hoc analysis, MH was assessed by CD Endoscopic Index of Severity [CDEIS], Simple Endoscopic Score for CD [SES-CD], and Colonic and Ileal Global Histologic Disease Activity Scores [CGHAS/IGHAS].
resultsBaseline endoscopic severity was similar across segments. At Week 52, mean changes in CDEIS surface involved and ulcerated surface were -68.5% to -90.6% in the rectum, sigmoid/left colon, and transverse colon compared with -22.3% to -50.0% in the right colon and ileum. Favourable shifts by Week 52 in ulcer size and ulcerated surfaces per SES-CD were more pronounced in the rectum, sigmoid/left colon, and transverse colon vs the right colon and ileum. At Week 52, CGHAS and IGHAS healing was more common in the colon [28.3%] vs the ileum [21.2%].
conclusionsThis analysis suggests differing propensities of the ileocolonic segments to heal endoscopically during adalimumab treatment. In the sigmoid/left and transverse colon, higher MH rates may be achieved, compared with the ileum, in patients with moderate to severe CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.